Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Enanta Pharmaceuticals (NASDAQ:ENTA) has announced an upcoming conference call and webcast scheduled for Monday, December 9 at 8:30 a.m. ET. The event will present topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in children with respiratory syncytial virus (RSV). The study focused on both hospitalized and non-hospitalized children aged 28 days to 36 months.
The live webcast will be accessible through the company’s website under the ‘Events & Presentations’ section in the investors area. Participants joining by phone are advised to register at least 15 minutes before the call to receive dial-in information. The webcast recording will remain available on Enanta’s website for approximately 30 days after the event.
Enanta Pharmaceuticals (NASDAQ:ENTA) ha annunciato una prossima conferenza telefonica e webcast programmata per lunedì 9 dicembre alle 8:30 ET. L’evento presenterà i risultati preliminari degli RSVPEDs, uno studio di Fase 2 pionieristico in pediatria che valuta il zelicapavir nei bambini affetti da virus respiratorio sinciziale (RSV). Lo studio si è concentrato su bambini ricoverati e non ricoverati di età compresa tra 28 giorni e 36 mesi.
La diretta webcast sarà accessibile tramite il sito web dell’azienda nella sezione ‘Eventi & Presentazioni’ nell’area investitori. Ai partecipanti che si uniscono telefonicamente si consiglia di registrarsi almeno 15 minuti prima della chiamata per ricevere le informazioni di accesso. La registrazione della webcast rimarrà disponibile sul sito di Enanta per circa 30 giorni dopo l’evento.
Enanta Pharmaceuticals (NASDAQ:ENTA) ha anunciado una próxima conferencia telefónica y webcast programada para el lunes 9 de diciembre a las 8:30 a.m. ET. El evento presentará los resultados preliminares de los RSVPEDs, un estudio de Fase 2 pionero en pediatría que evalúa el zelicapavir en niños con virus respiratorio sincitial (RSV). El estudio se centró en niños hospitalizados y no hospitalizados de 28 días a 36 meses de edad.
El webcast en vivo será accesible a través del sitio web de la empresa en la sección ‘Eventos y Presentaciones’ del área de inversores. Se aconseja a los participantes que se unan por teléfono registrarse al menos 15 minutos antes de la llamada para recibir la información de acceso. La grabación del webcast permanecerá disponible en el sitio web de Enanta durante aproximadamente 30 días después del evento.
Enanta Pharmaceuticals (NASDAQ:ENTA)는 12월 9일 월요일 오전 8시 30분 ET에 예정된 전화 회의 및 웨비나를 발표했습니다. 이 행사에서는 호흡기세포융합바이러스(RSV)에 감염된 어린이를 대상으로 한 2상 연구인 RSVPEDs의 주요 결과가 발표될 예정입니다. 연구는 입원 및 비입원 아동을 대상으로 하였으며, 연령은 28일에서 36개월까지입니다.
생중계는 회사 웹사이트의 ‘이벤트 및 발표’ 섹션에서 투자자 영역을 통해 접근할 수 있습니다. 전화로 참여하는 경우 통화 15분 전에 등록하여 접속 정보를 받을 것을 권장합니다. 웨비나 기록은 행사 후 약 30일 동안 Enanta 웹사이트에서 이용 가능합니다.
Enanta Pharmaceuticals (NASDAQ:ENTA) a annoncé une prochaine conférence téléphonique et un webcast programmés pour le lundi 9 décembre à 8h30 ET. L’événement présentera les résultats préliminaires des RSVPEDs, une étude de Phase 2 novatrice en pédiatrie évaluant le zelicapavir chez des enfants atteints du virus respiratoire syncytial (RSV). L’étude était axée sur les enfants hospitalisés et non hospitalisés âgés de 28 jours à 36 mois.
Le webcast en direct sera accessible via le site de l’entreprise dans la section ‘Événements & Présentations’ de la zone investisseurs. Il est conseillé aux participants se joignant par téléphone de s’inscrire au moins 15 minutes avant l’appel pour recevoir les informations de connexion. L’enregistrement du webcast restera disponible sur le site d’Enanta pendant environ 30 jours après l’événement.
Enanta Pharmaceuticals (NASDAQ:ENTA) hat eine bevorstehende Telefonkonferenz und ein Webcast für Montag, den 9. Dezember um 8:30 Uhr ET angekündigt. Bei der Veranstaltung werden die Ergebnisse der RSVPEDs vorgestellt, einer Phase-2-Studie, die zelicapavir bei Kindern mit respiratorischem Synzytialvirus (RSV) bewertet, und die sowohl hospitalisierte als auch nicht-hospitalisierte Kinder im Alter von 28 Tagen bis 36 Monaten fokussiert.
Das Live-Webcast wird über die Website des Unternehmens im Abschnitt ‘Veranstaltungen & Präsentationen’ im Investorenbereich zugänglich sein. Teilnehmer, die sich telefonisch einwählen, wird geraten, sich mindestens 15 Minuten vor dem Anruf zu registrieren, um die Einwahlinformationen zu erhalten. Die Aufzeichnung des Webcasts bleibt etwa 30 Tage nach der Veranstaltung auf der Website von Enanta verfügbar.
- Conference call and webcast to discuss data on Monday, December 9 at 8:30 a.m. ET
WATERTOWN, Mass.–(BUSINESS WIRE)– Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV).
Conference Call and Webcast Information
The live webcast on Monday, December 9 at 8:30 a.m. ET can be accessed at “Events & Presentations” in the investors section of Enanta’s website. To participate by phone, please register for the call here. It is recommended that participants register a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta’s website for approximately 30 days following the event.
About Zelicapavir
Zelicapavir, Enanta’s lead N-protein inhibitor, is being developed for the treatment of RSV infection, and has been granted Fast Track designation by the U.S. Food and Drug Administration. Zelicapavir is a nanomolar inhibitor of both RSV-A and RSV-B activity. Zelicapavir is differentiated from RSV fusion inhibitors as the N-protein inhibitor targets the virus’ replication machinery and has demonstrated a high barrier to resistance in vitro. In preclinical studies, zelicapavir maintained antiviral potency across all clinical isolates tested and was active against viral variants resistant to other mechanisms. Zelicapavir demonstrated a favorable safety, pharmacokinetic and drug-drug interaction profile in an extensive Phase 1 program. In a Phase 2 challenge study, zelicapavir achieved highly statistically significant (p<0.001) reductions in RSV viral load and clinical symptoms compared to placebo and was safe and well-tolerated, with infrequent adverse events. Zelicapavir is currently being evaluated in RSVHR, a Phase 2b study in the elderly and/or those with congestive heart failure, chronic obstructive pulmonary disease (COPD) or asthma.
About Respiratory Syncytial Virus
RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under one year of age in the United States and a significant cause of respiratory illness in older adults and immunocompromised individuals.1 According to the Centers for Disease Control and Prevention, virtually all children in the United States get an RSV infection by the time they are two years old and one to two out of every 100 children younger than six months of age with an RSV infection may need to be hospitalized.2 Globally, there are an estimated 33 million cases of RSV annually in children less than five years of age, with about 3 million hospitalized and up to approximately 100,000 dying each year from complications associated with the infection.3 RSV represents a significant health threat for adults older than 65 years of age, with an estimated 177,000 hospitalizations and 14,000 deaths associated with RSV infections annually in the United States.4
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including with respect to the prospects for further development and advancement of zelicapavir for the treatment of RSV. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the development risks of early stage discovery efforts in the disease areas in Enanta’s research and development pipeline, such as RSV; the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for RSV; Enanta’s limited clinical development experience; Enanta’s need to attract and retain senior management and key scientific personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. All forward-looking statements contained in this release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Enanta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
- Centers for Disease Control & Prevention – Respiratory Syncytial Virus Last accessed: December 2024.
- Centers for Disease Control & Prevention – RSV in Infants and Young Children Last accessed: December 2024.
- Shi, Ting et al. “Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.” Lancet (London, England) vol. 390,10098 (2017): 946-958. doi:10.1016/S0140-6736(17)30938-8
- Falsey, Ann R et al. “Respiratory syncytial virus infection in elderly and high-risk adults.” The New England Journal of Medicine vol. 352,17 (2005): 1749-59. doi:10.1056/NEJMoa043951
View source version on businesswire.com: https://www.businesswire.com/news/home/20241206627146/en/
Media and Investors Contact:
Jennifer Viera
617-744-3848
Source: Enanta Pharmaceuticals, Inc.
FAQ
What is the purpose of Enanta Pharmaceuticals’ Phase 2 RSVPEDs study for zelicapavir (ENTA)?
The RSVPEDs study is evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). It is a first-in-pediatrics Phase 2 study.
When will Enanta Pharmaceuticals (ENTA) present the topline results for their RSVPEDs study?
Enanta Pharmaceuticals will present the topline results during a conference call and webcast on Monday, December 9 at 8:30 a.m. ET.
How can investors access Enanta Pharmaceuticals’ (ENTA) RSVPEDs study results presentation?
Investors can access the live webcast through the ‘Events & Presentations’ section of Enanta’s website, or participate by phone by registering for the call. The webcast recording will be available for approximately 30 days afterward.
